Prevention of Bronchiectasis in Infants With Cystic Fibrosis

Learn more about:
Related Clinical Trial
COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic Identification of Microbiome of Bronchiectasis in Chinese Population. Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19) Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound COPD Patient-Powered Research Network Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis Seoul National University Airway Registry VX-770 for the Treatment of Chronic Bronchitis Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis Adherence to Airway Clearance. Novel Approaches to Improving Adherence Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Prevalence of Respiratory Impairment During IBD The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions The Effect of Proprioceptive Neuromuscular Facilitation (PNF) Technique for Children With Chronic Pulmonary Diseases. Effect of HFCWO Vests on Spirometry Measurements Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects Biological Determinants of Sputum Rheology in Chronic Airway Diseases A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease The Prevalence of Gastro-oesophageal Reflux in Chronic Lung Disease High Dose Inhaled Mannitol Study Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa Respiratory Muscle Strength in Bronchiectasis: Repeatability and Reliability Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) Evaluation Of The Lung Microbiome In NTM Bronchiectasis Inhalation Flow Rate-study Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis Inspiratory Flow and Volumes in Bronchiectatics Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD Evaluation of Periodontal Treatment in Patients With Bronchiectasis Long Term Nebulised Gentamicin in Patients With Bronchiectasis Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis. Study of the Effect of FLUTTER® VRP1 (PEP and Oscillating High Frequency). Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR) Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis Physiological Effects of Expiration With the Glottis Open in Lateral Posture (ELTGOL) and Flutter Valve in Patients With Bronchiectasis Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis Safety and Efficacy of Bronchitol in Bronchiectasis Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis Feasibility of Interval Exercise in Bronchiectasis Prognosis of Bronchiectasis in Children–A Multicenter Prospective Cohort Study Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis Effects of Inspiratory Muscle Training in Patients With Bronchiectasis Acute Effects of a Flutter Device and Chest Wall Compression on Respiratory System Impedance in Bronchiectasis Patients Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Cardiovascular Comorbidities and Bronchiectasis The Effect of Different Virtual Reality-Based Exercise Trainings on Pulmonary Function, Respiratory and Peripheral Muscle Strength, Functional Capacity and Balance in Children With Bronchiectasis Functional Respiratory Imaging in Bronchiectasis Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis Long-term Prognosis of Children With Bronchiectasis Treated With Low-dose Erythromycin Intervention Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Feasibility Study of the AffloVest in Bronchiectasis Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa The Effect of Theophylline in the Treatment of Bronchiectasis Bronchiectasis and Long Term Azithromycin Treatment Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Pain Mechanisms in Patients With Bronchiectasis Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation Efficacy of Azithromycin in Treatment of Bronchiectasis Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease? Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis Efficacy of Budesonide-Formoterol in Bronchiectasis Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis Mucus Solids Concentration in Patients With Bronchiectasis Target Validation and Discovery in Idiopathic Bronchiectasis Exercise Capacity in Bronchiectasis Resection Physical Activity in Bronchiectasis The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Effect of AIRVO Heated Humidification in Bronchiectasis A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis Autologous Transplantation of Bronchial Basal Cells for Treatment of Bronchiectasis Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis: A Randomized, Multi-center, Double-blind Study Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis The Effect of Bronchiectasis on the Exacerbation and Mortality in COPD Inhaled A1AT in Adult Stable Bronchiectasis Prevention of Bronchiectasis in Infants With Cystic Fibrosis Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis Physical Capacity in Patients With Bronchiectasis Before and After Rehabilitation Program In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis Bronchiectasis Effect in COPD Patients Prevalence and Characteristics of Patients With Bronchiectasis Comorbid Nontuberculous Mycobacteria Aetiology of Children With Bronchiectasis in China Macrolides in COPD- Bronchiectasis Overlap Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis Comparison of Sit-to-stand Test With Six-minute Walk Test in Bronchiectasis and Healthy Children Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls The PROspective German NOn-CF bronchiectaSIS Patient Registry The BRIDGE Study – Bronchiectasis Research Involving Databases, Genomics and Endotyping Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis Evaluation of Medical and Nursing Management for Bronchiectasis A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting The Establishment of China Bronchiectasis Registry and Research Collaboration Short-and Long-term Effects of a Home-based Rehabilitation Program in Patients With Bronchiectasis The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults Bronchiectasis: Evaluation of an Educational Intervention Prevalence of Bronchiectasis in COPD Patients ELTGOL and Bronchiectasis. Respiratory Therapy Bacteriology and Inflammation in Bronchiectasis Different Phenotypes of Bronchiectasis Effects of Traditional Chinese Medicine on Bronchiectasis Patients The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis

Brief Title

Prevention of Bronchiectasis in Infants With Cystic Fibrosis

Official Title

A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.

Brief Summary

      The general aim of this project is to conduct a randomized, double-blind, placebo-controlled
      clinical trial of azithromycin to determine whether treatment from infancy is safe and will
      prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF
      clinics in Australia and New Zealand and treated from 3 months to three years of age. The
      primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years
      of age. Safety and mechanistic evaluations will also be undertaken.
    

Detailed Description

      SYNOPSIS OF PROTOCOL

      Title Multi-centre randomized placebo-controlled study of azithromycin in the primary
      prevention of radiologically-defined bronchiectasis in infants with Cystic Fibrosis

      Clinical Phase Phase 3

      Protocol Number: AZI001

      TGA Reference Number:

      Protocol Co-Chairs: Peter D. Sly & Stephen M. Stick Microbiology Consultant: Lisa Saiman CT
      Consultant: Harm Tiddens Statistical Consultant: Nicholas deKlerk

      Study Design Randomized, double-blind parallel groups. Participants will be randomized into
      one of the following 2 groups on a 1:1 ratio with 65 participants per group;

      Group A: 10 mg/kg (as 200mg/5ml) azithromycin three times weekly for three years added to
      standard CF therapy.

      Group B: matched placebo three times weekly for three years added to standard CF therapy.

      Accrual Objective 130 children

      Accrual Period 24 months

      Study Duration 36 months

      Countries: Australia and New Zealand

      Sites: Brisbane Au, Sydney, Au, Melbourne Au, Adelaide Au, Perth Au,Auckland Nz, Christchurch
      Nz.

      Primary Endpoint The primary endpoint is the proportion of children with
      radiologically-defined bronchiectasis at age 3 years.

      Secondary Endpoints

        -  The extent and severity of bronchiectasis at age 3 years

        -  The volume of trapped gas at age 3 years

        -  CF-related quality of life

        -  Time to first pulmonary exacerbation

        -  Proportion of participants experiencing a pulmonary exacerbation

        -  Number of courses of inhaled or oral antibiotics

        -  Number of days of inhaled antibiotics

        -  Incidence of hospitalizations/Accident and Emergency department (A&E) visits for an
           acute respiratory exacerbation

        -  Number of days hospitalized for an acute respiratory exacerbation

        -  Number of days if intravenous antibiotics

        -  Body mass index at 3 years of age.

      Exploratory Endpoints

        -  Markers of neutrophilic inflammation

        -  Markers of oxidative stress

        -  Composition of airway flora

      Safety Endpoints

        -  Proportion of participants growing P. aeruginosa in BAL

        -  Age of acquisition of P. aeruginosa in BAL

        -  Emergence of macrolide-resistant S. aureus, small colony variant S. aureus and
           non-tuberculous mycobacteria (NTM)

        -  Treatment-related adverse events

        -  Haematology and clinical chemistry

      Inclusion Criteria Participants who meet all of the following criteria are eligible for
      enrolment as study participants:

        1. Children of either sex with a diagnosis of CF following detection via New Born Screening
           (NBS) for cystic fibrosis

        2. Participants who, in the opinion of the Investigator, are able to comply with the
           protocol for its duration

        3. Written informed consent signed and dated by parent/legal guardian according to local
           regulations

      Exclusion Criteria Participants who meet any of these criteria are not eligible for enrolment
      as trial participants:

        1. Born <30 weeks gestation

        2. Prolonged mechanical ventilation in the first 3 months of life

        3. Participation in another randomized controlled trial within the 3 months preceding
           inclusion in this study

        4. A significant medical disease or condition other than CF that is likely to interfere
           with the child's ability to complete the entire protocol

        5. Previous major surgery except for meconium ileus

        6. Macrolide hypersensitivity

      Treatment Description ZITHROMAX® (azithromycin)

      Study Procedures The study participants will be stratified by investigational site and
      randomly assigned to either azithromycin or placebo for three years.

      Statistical Considerations Participants will be randomized in blocks to the treatment group
      or the placebo group using a one-to-one ratio. Randomization will be stratified by study
      site. This will ensure an approximately equal allocation to each group within each site.

      Interim Analyses Interim analyses will occur when the first 50% of children (n=33 per group
      have completed the 12 month CT and when all subjects have completed the 12 month CT. Interim
      analyses will determine safety or success (unethical to continue).

      Stopping Rules Study enrolment may be stopped if any of the following events occur:

        -  Death of a participant that is related to study treatment.

        -  The trial meets the definition of futility or success at either of the planned interim
           analyses
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Proportion of children with radiologically-defined bronchiectasis

Secondary Outcome

 extent and severity of bronchiectasis

Condition

Cystic Fibrosis

Intervention

Azithromycin

Study Arms / Comparison Groups

 azithromycin liquid preparation
Description:  azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

132

Start Date

April 2012

Completion Date

May 2021

Primary Completion Date

May 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Children of either sex with a diagnosis of CF following detection via New Born
             Screening (NBS) for cystic fibrosis

          2. Participants who, in the opinion of the Investigator, are able to comply with the
             protocol for its duration

          3. Written informed consent signed and dated by parent/legal guardian according to local
             regulations

        Exclusion Criteria:

          1. Born <30 weeks gestation

          2. Prolonged mechanical ventilation in the first 3 months of life

          3. Participation in another randomized controlled trial within the 3 months preceding
             inclusion in this study

          4. A significant medical disease or condition other than CF that is likely to interfere
             with the child's ability to complete the entire protocol

          5. Previous major surgery except for meconium ileus

          6. Macrolide hypersensitivity
      

Gender

All

Ages

6 Weeks - 6 Months

Accepts Healthy Volunteers

No

Contacts

Peter D Sly, MMBS MD DSc, , 

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT01270074

Organization ID

AZI001

Secondary IDs

STICK10K0

Responsible Party

Principal Investigator

Study Sponsor

The University of Queensland

Collaborators

 Telethon Kids Institute

Study Sponsor

Peter D Sly, MMBS MD DSc, Study Chair, The University of Queensland


Verification Date

November 2019